zuruck zur Themenseite

Artikel und Hintergründe zum Thema

Peter Nussbaum's successor

Martin Schrüfer,

Thomas Herren new CFO at Gilgen Logistics

Thomas Herren is the new CFO of the Swiss family-owned company Gilgen Logistics. He replaces Peter Nussbaum on the Executive Board, who is taking early retirement.

The management of Gilgen Logistics, from left to right: Ruedi Weber, Jakob Gilgen, Daniel Gilgen and Thomas Herren. © Gilgen Logistics

Thomas Herren joins the company and takes over the Finance and Administration division. In addition to the Finance & Controlling unit, this division is responsible for other central services and ICT. IT plays a significant role in driving forward the digitalization of internal and external processes. This has been a strategic focus of the intralogistics company for some time, and Tobias Soltermann has also been in the lead here for a few months.

Thomas Herren has worked for the energy company BKW for the past 16 years in various functions. Initially as a specialist in Consolidation & Accounting and later as Head of the central Financial Accounting unit and as Investor Relations Officer of the BKW Group. Prior to that, he worked as an auditor for industrial companies.

The current CFO, Peter Nussbaum, will take early retirement at his own request at the end of 2022 after a total of 34 years at Gilgen Logistics. "The Gilgen owner family would like to thank Peter Nussbaum for his great personal commitment to the company and wish him all the best for the future," reads a press release.

  • Xing Icon
  • LinkedIn Icon
Advertisement
Advertisement
Back to topic page
Advertisement

You might also be interested in

Advertisement
Advertisement
Advertisement
Advertisement

Logimat 2025

The Anton Cloud is coming

Anton Software, provider of the EVA shipping and export system for 35 years, will present two innovations at Logimat 2025 - the Anton Cloud, a plus in terms of relieving the burden on in-house IT departments and reducing costs as well as secure...

read more...
Advertisement
Advertisement
Advertisement
Subscribe to our newsletter
Advertisement
Back to home